Lftd Partners Inc (LIFD) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Lftd Partners Inc   (LIFD)


Lftd Partners Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics



LIFD Gross Profit Margin (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Revenue Change -15.69 %
Seq. Revenue Change -4.95 %
Revenue In Millions $8.71
Gross Profit Margin 7.48 %
Gross Profit Margin Total Ranking #
Gross Profit In Millions $0.65
Y / Y Gross Profit Change -79.94 %
Seq. Gross Profit Change -


Commenting Second Quarter 2026 Gross Profit Margin
Lftd Partners Inc achieved Gross Profit of $1 millions compare to Gross Loss of $-1.71 millions booked in the previous quarter. Despite the sequential Revenue deterioration in Q2 of -4.95 % Lftd Partners Inc managed to reduce Cost of Sales and turn into profitability by achieving a Gross Profit of 1 compare to Gross Loss of $-1.71 millions realized in the previous quarter. Company accomplished Gross Profit Margin of 7.48 %, below company average.


Observing second quarter 2026 results within Major Pharmaceutical Preparations industry Lftd Partners Inc has achieved highest Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to , from total ranking in the previous quarter at 2467.
Learn about Gross Margin
LIFD's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Gross Profit Margin Statistics
High Average Low
67.01 % 36.42 % 6.38 %
(Mar 31 2012)  




Other Gross Profit Margin Profitability Ratios
LIFD's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
LIFD's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for LIFD's Competitors
Gross Profit Margin Profit Margin for Lftd Partners Inc 's Suppliers
Gross Profit Margin Profit Margin for LIFD's Customers

You may also want to know
LIFD's Annual Growth Rates LIFD's Profitability Ratios LIFD's Asset Turnover Ratio LIFD's Dividend Growth
LIFD's Roe LIFD's Valuation Ratios LIFD's Financial Strength Ratios LIFD's Gross Profit Growth
LIFD's Roa LIFD's Inventory Turnover Ratio LIFD's Growth Rates LIFD's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Aspire Biopharma Holdings Inc   19.47 %$ 0.012  Millions$ 0.063  Millions
Rockwell Medical inc   18.24 %$ 3.243  Millions$ 17.780  Millions
Igc Pharma Inc   18.11 %$ 0.048  Millions$ 0.265  Millions
Jaguar Health Inc   15.84 %$ 0.194  Millions$ 1.225  Millions
Hcw Biologics Inc   10.82 %$ 0.028  Millions$ 0.257  Millions
China Pharma Holdings Inc  8.81 %$ 0.084  Millions$ 0.948  Millions
Lftd Partners Inc   7.48 %$ 0.651  Millions$ 8.705  Millions
Biora Therapeutics Inc   6.27 %$ 0.202  Millions$ 3.215  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.